4.6 Article

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis

Kim A. Papp et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

Craig Leonardi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Letter Dermatology

Latitude and psoriasis prevalence

Christine C. Jacobson et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)

Review Medicine, General & Internal

Mechanisms of Disease: Psoriasis.

Frank O. Nestle et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Article Dermatology

Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells

Michelle A. Lowes et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)

Review Multidisciplinary Sciences

Pathogenesis and therapy of psoriasis

Michelle A. Lowes et al.

NATURE (2007)

Article Dermatology

Traditional systemic treatments have not fully met the needs of psoriasis patients: Results from a national survey

T Nijsten et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)